SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX 2023
Fresenius Group compiles and discloses data based on the metrics of the Sustainability Accounting Standards Board (SASB) in its Index 2023. Going forward, we continuously strive to improve our disclosure of quantitative metrics and further enhance our SASB reporting. With this process, we are acknowledging the importance of the SASB standard among our investors.
In the 2023 reporting year, we used the SASB standards updated in 2023. These will officially replace the standards last updated in 2018 as of 2025, but are already available for implementation. Our disclosures are based on the Sustainable Industry Classification System (SICS) industries within the health industry sector, with a focus on those sectors that best reflect our different business fields: Biotechnology & Pharmaceuticals (BP), Health Care Delivery (DY), Health Care Distributors (DI), and Medical Equipment & Supplies (MS). Due to the diversified business model of Fresenius SE & Co. KGaA and its subsidiaries, only those indicators of the identified industry standards which are relevant for our operations are included in the index provided.
The majority of references within this index refer to the Fresenius 2023 Group Annual Report (see: https://annualreport.fresenius.com/wp-content/uploads/sites/12/2024/02/Fresenius_Annual_Report_2023.pdf), including the Fresenius 2023 Separate Group Non-financial Report (see pages 102 ff. of the Group Annual Report 2023).
Unless otherwise stated, all reported data are as of December 31, 2023.
Topic | Code | Accounting metric | Comment and link |
Biotechnology & | Pharmaceuticals | ||
Safety of | HC-BP-210a.1 | Discussion, by world region, of | Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and |
Clinical Trial | management process for | relevant guidelines or policies. Information provided focuses on clinical studies in pharmaceutical approval processes in our healthcare products | |
Participants | ensuring quality and patient | market segment and innovative treatment concepts in the healthcare services market segment. It is ensured that scientific, ethical and legal | |
safety during clinical trials | requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is | ||
provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to | |||
participate. | |||
Fresenius Group Non-financial Report 2023: Innovation > Our approach > Product innovation | |||
> Clinical studies in pharmaceutical approval processes (pg. 133 f.) | |||
> Innovative treatment concepts (pg. 135 f.) | |||
Caring for Human Rights: https://www.fresenius.com/human-rights | |||
HC-BP-210a.2 | Number of inspections related to | Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and | |
clinical trial management and | relevant guidelines or policies. Information is provided for all business segments with a focus on clinical study management in our hospitals. It is | ||
pharmacovigilance that resulted | ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are | ||
in: (1) entity voluntary | carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free | ||
remediation or (2) regulatory or | to decide whether or not to participate. Inspections conducted by external bodies are not published separately. At Fresenius Kabi, the total number of | ||
administrative actions taken | inspections in the reporting year is provided. | ||
against the entity | Fresenius Group Non-financial Report 2023: | ||
Well-being of the patient > Patient and product safety > Our approach > Healthcare products market segment: Fresenius Kabi > Guidelines and | |||
regulations: Table "Audits and inspections" (pg. 123) | |||
HC-BP-210a.3 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius Group Annual Report 2023 - Note 31: Commitments and | |
as a result of legal proceedings | contingencies (pg. 327 f.) | ||
associated with clinical trials in | |||
developing countries | |||
March 2024 | Page 1 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Access to | HC-BP-240a.1 | Description of actions and | Fresenius Group Non-financial Report 2023: Well being of patients | |
Medicines | initiatives to promote access to | > Access to healthcare and medicine (pg. 116) | ||
health care products for priority | > Access to healthcare and medicine >Our approach (S.116 f.) | |||
diseases and in priority | > Access to healthcare and medicine > Patient support in crisis and emergeny situations (S. 118) | |||
countries as defined by the | ||||
Access to Medicine Index | Cooperation and social activities 2023: https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/ | |||
HC-BP-240a.2 | List of products on the WHO List | Fresenius Kabi has one entity mentioned as API manufacturing site for two listed products on the WHO List of Prequalified Medicinal Products as of | ||
of Prequalified Medicinal | the reporting year 2023. For more information, click here: | |||
Products as part of its | https://extranet.who.int/prequal/medicines/ha479 | |||
Prequalification of Medicines | https://extranet.who.int/prequal/medicines/ha480 | |||
Programme (PQP) | ||||
Drug Safety | HC-BP-250a.1 | Products listed in public medical | Fresenius Group Non-financial Report 2023: | |
product safety or adverse event | Well being of patients > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Product risk management (pg. 124) | |||
alert databases | Please refer to MedWatch: The FDA Safety Information and Adverse Event Reporting Program: https://www.fda.gov/safety/medwatch-fda-safety- | |||
information-and-adverse-event-reporting-program | ||||
HC-BP-250a.2 | Number of fatalities associated | Fresenius Group Non-financial Report 2023: Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius | ||
with products | Kabi | |||
> Guidelines and regulations (pg. 122 f.) | ||||
> Monitoring and reporting systems (pg. 123 f.) | ||||
HC-BP-250a.3 | (1) Number of recalls issued, | Fresenius Group does not report on the numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall execution in | ||
(2) total units recalled | order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand in cooperation with the respective authority. For | |||
information on our approach towards recalls, see: | ||||
Fresenius Group Non-financial Report 2023: | ||||
Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Product risk management (pg. 124) | ||||
HC-BP-250a.5/ | Number of enforcement actions | We report on inspections and enforcement actions taken, if material for the operating business, in our quarterly and annual reports. | ||
HC-MS-250a.4 | taken in response to violations | |||
of good manufacturing practices | Fresenius Group Annual Report 2023: | |||
(GMP) or equivalent standards, | Significant characteristics of the Fresenius risk management system and entire internal control system (pg. 87 f.) | |||
by type | Fresenius Group Non-financial Report 2023: | |||
Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > Guidelines and regulations (pg. 123): | ||||
Table "Audits and inspections" | ||||
Counterfeit | HC-BP-260a.1/ | Description of methods and | Fresenius Group Non-financial Report 2023: | |
Drugs | HC-DI-260a.1 | technologies used to maintain | > Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Labeling and product information | |
traceability of products | (pg. 124); | |||
throughout the supply chain and | > Digital transformation > Our approach >Digital processes and applications (pg. 139 ff.) | |||
prevent counterfeiting | Fresenius Kabi Drug Supply Chain Security Act (DSCSA): https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa | |||
Ethical | HC-BP-270a.1/ | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | |
Marketing | HC-MS-270a.1 | as a result of legal proceedings | contingencies (pg. 327 f.) | |
associated with false marketing | ||||
claims | ||||
March 2024 | Page 2 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
HC-BP-270a.2/ | Description of code of ethics | Fresenius Kabi: https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf | ||
HC-MS-270a.2 | governing promotion of off-label | |||
use of products | Fresenius Group Non-financial Report 2023: | |||
Well being of the patient > Patient and product safety > Healthcare products market segment >Labeling and product information (pg. 124) | ||||
Employee | HC-BP-330a.1 | Discussion of talent recruitment | We place special importance on those employees, who support our ambitions on innovative treatment concepts and product innovations. For | |
Recruitment, | and retention efforts for | overarching measures, please see: | ||
Development & | scientists and research and | |||
Retention | development personnel | Fresenius Group Non-financial Report 2023: | ||
Innovation (pg. 132 ff.) | ||||
Employees > Our approach | ||||
>Recruitment (pg. 149 f.) | ||||
> Employee development (pg. 150 ff.) | ||||
> Employee retention (pg. 152) | ||||
HC-BP-330a.2 | (1) Voluntary and (2) involuntary | Fresenius discloses the voluntary turnover for each business segment and for the Group per region, but not as a break-down for management levels. | ||
turnover rate for: (a) | We aim to improve the reporting scope on recuritment data going forward and assess internally to add further KPIs for this aspect. | |||
executives/senior managers, (b) | ||||
midlevel managers, (c) | Fresenius Group Non-financial Report 2023: | |||
professionals, and (d) all others | Employees > Our approach >Employee retention (pg. 152) | |||
Voluntary turnover by region (reporting started in 2021): | ||||
ESG KPI Overview: https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/ | ||||
Business Ethics | HC-BP-510a.1/ | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | |
HC-DI-510a.2/ | as a result of legal proceedings | contingencies (pg. 327 f.) | ||
HC-MS-510a.1 | associated with corruption and | |||
bribery | ||||
HC-BP-510a.2/ | Description of code of ethics | Fresenius Group Non-financial Report 2023: | ||
HC-MS-510a.2 | governing interactions with | > Strategy and management > Stakeholders and partnerships >Transparency in the healthcare sector (pg. 111) | ||
health care professionals | > Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Labeling and product information | |||
(pg. 124) | ||||
> Compliance and integrity > Compliance > Our approach >Guidelines and regulations (pg. 171 f.) | ||||
Fresenius Group Compliance: https://www.fresenius.com/compliance | ||||
Activity metrics | HC-BP-000.A | Number of patients treated | Fresenius Group Non-financial Report 2023: | |
Well being of the patient > Patient and product safety > Healthcare services market segment: Fresenius Helios >Treatment quality (pg. 126) | ||||
HC-BP-000.B | Number of drugs (1) in portfolio | Please refer to our Capital Markets Day 2023: https://www.fresenius.com/sites/default/files/2023-05/Fresenius_CMD_2023_Presentation_0.pdf | ||
and (2) in research and | ||||
development (Phases 1-3) | ||||
March 2024 | Page 3 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Health Care Delivery | ||||
Energy | HC-DY-130a.1 | (1) Total energy consumed, (2) | Fresenius Group Non-financial Report 2023: | |
Management | percentage grid electricity, (3) | Environment > Climate protection - energy and emissions > Our approach > Energy Consumption (pg. 192 ff) | ||
percentage renewable | (1) Conversion: Fresenius Group reports the total energy consumption in MWh. Converted into GJ, Fresenius Group consumed 11,124,000 GJ in 2023 | |||
(3.09 million MWh). | ||||
(2) 38.07% | ||||
(3) 21% of total energy consumption (18% electricity (renewable), 3% renewable fuels) | ||||
Waste | HC-DY-150a.2 | Total amount of: (1) hazardous | We are providing information on hazardous and non-hazardous waste (Fresenius Kabi and Fresenius Helios), and on waste in relation to hospital beds | |
Management | and (2) non-hazardous | (Fresenius Helios) in our ESG KPI Overview: https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/ | ||
pharmaceutical waste, | ||||
percentage (a) incinerated, (b) | Fresenius Separate Group Non-financial Report 2023: | |||
recycled or treated and (c) | Environment > Waste and recycling management (pg. 189 f.) | |||
landfilled | ||||
Patient Privacy | HC-DY-230a.2 | Description of policies and | Fresenius Group Non-financial Report 2023: | |
& Electronic | practices to secure customers' | > Strategy and management > Stakeholders and partnerships > Stakeholder dialog in all areas >Transparency in the healthcare sector (pg. 111) | ||
Health Records | personal health data records | > Compliance and Integrity >Data protection (pg. 176 ff.) | ||
and other personal data | ||||
HC-DY-230a.3 | (1) Number of data breaches, (2) | Fresenius Group Non-financial Report 2023: Compliance and Integrity | ||
percentage involving (a) | > Compliance > Our approach > Organization and responsibilities >Reporting paths (pg. 170 f.) | |||
personal data only and (b) | > Data protection >Reporting systems (pg. 177) | |||
personal health data, (3) number | ||||
of customers affected in each | ||||
category, (a) personal data only | ||||
and (b) personal health data | ||||
HC-DY-230a.4 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | ||
as a result of legal proceedings | contingencies (pg. 327 f.) | |||
associated with data security | ||||
and privacy | ||||
Quality of Care | HC-DY-250a.2 | Number of serious reportable | Fresenius Group reports on serious reportable events with regard to treatments in hospitals and healthcare facilitities (Fresenius Helios). We provide | |
& Patient | events | information both on serious events as well as critical incidents in our Fresenius Group Non-financial Report 2023. | ||
Satisfaction | Fresenius Group Non-financial Report 2023: | |||
Well being of the patient > Patient and product safety > Halthcare services market segment: Fresenius Helios > Treatment quality >Patient safety | ||||
and reporting systems (pg. 127 f.) | ||||
HC-DY-250a.3 | Hospital-acquired condition | The Hospital-Acquired Condition rate is not calculated for hospitals and healthcare facilities in the business segments Fresenius Helios and Fresenius | ||
rates per hospital | Vamed. However, we report on indicators in our hospitals and healthcare facilities which are comparable to those of the HAC Score, please refer to: | |||
https://www.helios-gesundheit.de/qualitaet/erreger/ | ||||
Fresenius Group Non-financial Report 2023: | ||||
Well being of the patient >Patient and product safety (pg. 118 ff) | ||||
March 2024 | Page 4 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Management of | HC-DY-260a.1 | Description of policies and | Hygiene management at Fresenius Helios focuses on close monitoring of infections and pathogens, regular hygiene training for hospital staff, for | |
Controlled | practices to manage the number | example on correct hand disinfection, monitoring antibiotic consumption, and training physicians as antibiotic stewardship (ABS) specialists. The | ||
Substances | of prescriptions issued for | implementation of and compliance with hospital hygiene measures in the clinics is accompanied and monitored by our specially trained staff - e. g., | ||
controlled substances | hygiene specialist nurses, hospital hygienists, and hygiene officers. The Helios Group hygiene regulation is binding for all employees in all clinics of | |||
Helios Germany. It is based on the evidence-based recommendations of the Robert Koch Institute (RKI) and prescribes, among other things, hand | ||||
disinfection - especially before and after contact with patients - for physicians, nurses, medical staff, and other personnel, in accordance with the | ||||
guidelines of the WHO. Anomalies in consumption are recorded in targeted reviews. In this way, developments can be closely observed and analysed. | ||||
Fresenius Group Non-financial Report 2023: | ||||
Well being of the patient > Patient and product safety > Healthcare services market segment: Fresenius Helios >Hygiene management in hospitals | ||||
(pg. 128) | ||||
List of antibiotics and amount per antibiotic used in treatments overall and per clinic in Germany of Fresenius Helios: https://www.helios- | ||||
gesundheit.de/qualitaet/antibiotika/ (available in German language only) | ||||
Workforce | HC-DY-320a.1 | Total recordable incident rate | We disclose the lost time injury frequency rate (LTIFR) for Fresenius Kabi, Fresenius Helios in Spain and Fresenius Vamed. Fresenius Helios | |
Health & Safety | (TRIR) for (a) direct employees | Germany is currently implementing the LTIFR. | ||
and (b) contract employees | Fresenius Group Non-financial Report 2023: | |||
Occupational health and safety > Other work-related accidents and incidents (pg. 159) | ||||
Employee | HC-DY-330a.1 | (1) Voluntary and (2) involuntary | We do not provide a split for physicians, non-physician healthcare practitioners but only for all employees in a business segment. However, the | |
Recruitment, | turnover rate for: (a) physicians, | majority of employees are nurses and medical staff. | ||
Development & | (b) non-physician health care | |||
Retention | practitioners, and (c) all other | Fresenius Group Non-financial Report 2023: | ||
employees | Employees > Our approach >Employee retention (pg. 152 f.) | |||
HC-DY-330a.2 | Description of talent recruitment | Fresenius Group Non-financial Report 2023: Employees > Our approach | ||
and retention efforts for health | > Employee development (pg. 150 ff.) | |||
care practitioners | > Employee retention (pg. 152) | |||
Climate Change | HC-DY-450a.1 | Description of policies and | Fresenius Group is currently assessing the impacts of climate change on our operating business. | |
Impacts on | practices to address: (1) the | In the future, we will assess the impact of Scope 3 emissions to include them in our targets as well. We will provide updates on these assessments in | ||
Human Health & | physical risks because of an | our non-financial reporting going forward. | ||
Infrastructure | increased frequency and | Fresenius Group Non-financial Report 2023: | ||
intensity of extreme weather | ||||
events, (2) changes in the | Strategy and management | |||
morbidity and mortality rates of | > Sustainability risks and controls (pg. 106 f.) | |||
illnesses and diseases | > Our sustainability goals and programs (pg. 107) | |||
associated with climate change | >EU-Taxonomy (pg. 111 ff.) | |||
and (3) emergency | Well being of patients > Access to healthcare and medicine >Patient support in crisis and emergency situations (pg. 118) | |||
preparedness and response | Environment | |||
> Environmental management > Our approach >Identification and management of environmental risks (pg. 186) | ||||
> Climate protection - energy and emissions (pg. 190 ff.) | ||||
Fraud & | HC-DY-510a.1 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | |
Unnecessary | as a result of legal proceedings | contingencies (pg. 327 f.) | ||
Procedures | associated with medical fraud | |||
March 2024 | Page 5 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Activity metrics | HC-DY-000.A | Number of (1) facilities and (2) | ESG KPI Overview: https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/ | |
beds, by type | ||||
HC-DY-000.B | Number of (1) inpatient | Fresenius Group Non-financial Report 2023: | ||
admissions and (2) outpatient | Well-being of the patient > Patient and product safety > Healthcare services market segment: Fresenius Helios >Treatment quality (pg. 126) | |||
visits | ||||
Health Care Distributors | ||||
Product Safety | HC-DI-250a.1 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | |
as a result of legal proceedings | contingencies (pg. 327 f.) | |||
associated with product safety | ||||
HC-DI-250a.2 | Description of efforts to minimize | Fresenius Group Annual Report 2023: Opportunities and risk report > Significant characteristics of the Fresenius risk management system and | ||
health and safety risks of | entire internal control system (pg. 87 f.) | |||
products sold associated with | ||||
toxicity/chemical safety, high | Fresenius Group Non-financial Report 2023: | |||
abuse potential, or delivery | Well being of the patient >Patient and product safety (pg. 118 f.) | |||
Counterfeit | HC-DI-260a.1/ | Description of methods and | see HC-BP-260a.1 | |
Drugs | HC-BP-260a.1 | technologies used to maintain | ||
traceability of products | ||||
throughout the distribution chain | ||||
and prevent counterfeiting | ||||
HC-DI-260a.2 | Discussion of due diligence | Suppliers related to product manufacturing are subject to qualification processes based on the relevance of the delivered material or service. In the | ||
process to qualify suppliers of | healthcare products market segment, the supplier's qualification and their recertification is regularly audited. | |||
drug products and medical | ||||
equipment and devices | Fresenius Group Non-financial Report 2023: | |||
> Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Guidelines and regulations (pg. | ||||
122 f.) | ||||
> Compliance and Integrity > Human rights >Supplier evaluation (pg. 183) | ||||
HC-DI-260a.3 | Discussion of process for | Fresenius Group Non-financial Report 2023: | ||
alerting customers and business | Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Product risk management (pg. 124) | |||
partners of potential or known | ||||
risks associated with counterfeit | Fresenius Kabi - Pharmaceutical Products: https://www.fresenius-kabi.com/us/pharmaceutical-products | |||
products | ||||
Business Ethics | HC-DI-510a.1 | Description of efforts to minimize | Fresenius Group Non-financial Report 2023: Compliance and integrity (pg. 169 ff.) | |
conflicts of interest and unethical | ||||
business practices | Fresenius Group Annual Report 2023: | |||
Corporate Governance > Corporate Governance Declaration >Independence and conflicts of interest (pg. 209) | ||||
HC-DI-510a.2 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | ||
as a result of legal proceedings | contingencies (pg. 327 f.) | |||
associated with bribery, | ||||
corruption, or other unethical | ||||
business practices | ||||
March 2024 | Page 6 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Activity metrics | HC-DI-000.A | Number of pharmaceutical units | We do not disclose the number of pharmaceutical units sold by product category, only sales by product segment. | |
sold by product category | #FutureFresenius - Advancing Patient Care: | |||
https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf (pg. 36) | ||||
HC-DI-000.B | Number of medical devices sold | We do not disclose the number of medical devices sold by product category, only sales by product segment. | ||
by product category | #FutureFresenius - Advancing Patient Care: | |||
https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf (pg. 36) | ||||
Medical Equipment | & Supplies | |||
Product Safety | HC-MS-250a.1 | (1) Number of recalls issued, | Fresenius Group does not report on the total numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall | |
(2) total units recalled | execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand with the respective authority. | |||
Fresenius Group Non-financial Report 2023: | ||||
Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Product risk management (pg. 124) | ||||
Example: Fresenius Kabi - Pharmaceutical Products | ||||
https://www.fresenius-kabi.com/us/pharmaceutical-products | ||||
https://www.fresenius-kabi.com/us/pharmaceutical-product-updates | ||||
See: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Fresenius&field_regulated_product_field=All | ||||
HC-MS-250a.2 | Products listed in any public | Please refer to the FDA Adverse Event Reporting: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program | ||
medical product safety or | ||||
adverse event alert database | Fresenius Group Non-financial Report 2023: | |||
Well being of the patient > Patient and product safety > Healthcare products market segment : Fresenius Kabi >Product risk management (pg. 124) | ||||
HC-MS-250a.4 | Number of enforcement actions | In the reporting year, there were no actions taken that stand against our quality goals. Guidelines of Good Manufacturing Practice (GMP) and current | ||
taken in response to violations | Good Manufacturing Practice (cGMP) guidelines are taken into account, see: | |||
of good manufacturing practices | ||||
(GMP) or equivalent standards, | Fresenius Group Non-financial Report 2023: | |||
by type | Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi >Guidelines and regulations (pg. 122 | |||
f.) | ||||
Ethical | HC-MS-270a.1 | Total amount of monetary losses | All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: Commitments and | |
Marketing | as a result of legal proceedings | contingencies (pg. 327 f.) | ||
associated with false marketing | ||||
claims | ||||
HC-MS-270a.2 | Description of code of ethics | We provide information in the codes of ethics and conduct of our business segments governing promotion of off-label use of products, if applicable. | ||
governing promotion of off-label | ||||
use of products | Example: Fresenius Kabi USA: https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf | |||
March 2024 | Page 7 / 8 | Fresenius SE Co. KGaA, Group ESG |
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX | ||||
Product Design | HC-MS-410a.2 | Total amount of products | In the health sector, the takeback, reuse and recycling of our products and materials is regulated on national level. Fresenius Group does not report on | |
& Lifecycle | accepted for takeback and | the total amount of products accepted for takeback and reused, recycled, or donated. | ||
Management | reused, recycled, or donated, | |||
broken down by: (1) devices and | ||||
equipment and (2) supplies | ||||
Supply Chain | HC-MS-430a.1 | Percentage of (1) entity's | Fresenius Group aims to improve the reporting scope on supply chain going forward. | |
Management | facilities and (2) Tier I suppliers' | |||
facilities participating in third- | Fresenius Group Non-financial Report 2023: Compliance and Integrity > Human rights >Supplier evaluation (pg. 183) | |||
party audit programs for | ||||
manufacturing and product | ||||
quality | ||||
HC-MS-430a.2 | Description of efforts to maintain | Fresenius Kabi - Drug supply chain security act: https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa | ||
traceability within the distribution | ||||
chain | Fresenius Group Non-financial Report 2023: Compliance and integrity > Human rights >Supplier evaluation (pg. 183) | |||
HC-MS-430a.3 | Description of the management | Before the EU Conflict Minerals Regulation came into force, Fresenius SE & Co. KGaA and its operating units already addressed this sensitive issue. | ||
of risks associated with the use | We do not purchase conflict minerals directly. However, it cannot be completely ruled out that they have been processed in components and | |||
of critical materials | semifinished products that we purchase and further process or use in our products. In this case, our purchasing guidelines apply, as do the relevant | |||
Group and business segment codes of conduct for dealing with suppliers and other business partners. | ||||
Fresenius Group Non-financial Report 2023: Compliance and integrity >Human rights (pg. 179 ff.) | ||||
Business Ethics | HC-MS-510a.1/ | Total amount of monetary losses | Fresenius Group reports on impacts from legal proceedings in the 2023 Group Annual Report, see Note 31: Commitments and Contingencies (pg. | |
HC-BP-510a.1/ | as a result of legal proceedings | 327 f.) | ||
HC-DI-510a.2 | associated with bribery or | |||
corruption | ||||
HC-MS-510a.2 | Description of code of ethics | Fresenius Code of Conduct: https://www.fresenius.com/sites/default/files/2022-01/FRS_Code_of_Conduct_ext.pdf | ||
governing interactions with | ||||
health care professionals | Fresenius Group Non-financial Report 2023: Strategy and management > Stakeholders and partnerships >Transparency in the healthcare sector | |||
(pg. 111) | ||||
March 2024 | Page 8 / 8 | Fresenius SE Co. KGaA, Group ESG |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 02 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2024 21:31:55 UTC.